Amgen’s Neulasta and Enbrel in 4Q17 and 2017

In 4Q17, Amgen’s (AMGN) Neulasta generated revenues of $1.1 billion, which reflected a 1% decline on a quarter-over-quarter basis. In 4Q17, Neulasta’s YoY (year-over-year) revenues remained flat. Lower unit demand primarily contributed to the decline in revenues for the quarter.

In 4Q17 in the US and international markets, Neulasta generated revenues of $969 million and $145 million, respectively.

In fiscal 2017, Neulasta generated revenues of $4.5 billion, which reflected a 2% decline YoY. In 2017 in the US and international markets, Neulasta generated revenues of $3.9 million and $603 million, respectively.

Lower unit demand primarily led to the decline of Neulasta revenues in 2017, which was partially offset by a higher net selling price compared to the previous year.

In 4Q17, Enbrel generated revenues of $1.4 billion, which reflected a 13% decline YoY and a 4% growth quarter-over-quarter. In 4Q17 in the US and international markets, Enbrel generated revenues of $1.4 billion and $55 million, respectively.

In fiscal 2017, Enbrel generated revenues of $5.4 billion, which reflected a 9% decline YoY. In 2017 in the US and international markets, Enbrel generated revenues of $5.2 billion and $227 million, respectively.

A lower net selling price primarily contributed to the decline in Enbrel revenues in 4Q17 and fiscal 2017.

Amgen commercializes Enbrel in the United States and Canada. Pfizer commercializes the drug outside the United States and Canada. In 4Q17, Pfizer generated revenues of $364 million from the sale of Enbrel, reflecting a 10% YoY decline.

Enbrel faces stiff competition from Johnson & Johnson’s (JNJ) Remicade (infliximab), AbbVie’s (ABBV) Humira, and Bristol-Myers Squibb’s (BMY) Orencia.